Cell therapy developer Cellular Biomedicine Group Inc. (CBMG) completed a $120 million series A financing, its first since becoming a private company. The funds will benefit the U.S. and China-based firm’s CAR T pipeline.
DUBLIN – Iomx Therapeutics AG raised €65 million (US$75.4 million) in a series B round, which will enable it to move its lead immuno-oncology program into the clinic. The funding will also allow it to take a second program into IND-enabling studies and to back-fill its pipeline with additional programs.
Like an overzealous Olympic runner, impressive and strong at the start of the race but dropping the pace with each subsequent lap, biopharma financings in 2021 grabbed headlines in the early months of the year, but they have significantly slowed down since then.
Exo Therapeutics Inc. has completed an oversubscribed series B financing for $78 million allowing the small-molecule company to continue developing therapies for treating cancer and inflammation.
Exo’s pipeline, created from its Exosight platform, has preclinical candidates that bind exosites, which are distal binding pockets for reprogramming enzyme activity. The exosite drugs include structural and computational biology, protein engineering and DNA-encoded libraries.
RSS
